Medtronic (NYSE:MDT) Issues FY 2025 Earnings Guidance

Medtronic (NYSE:MDT) issued an update on its FY 2025 earnings guidance on Saturday morning. The company provided EPS guidance of 5.400-5.500 for the period, compared to the consensus EPS estimate of 5.440. The company issued revenue guidance of $33.1 billion-$33.6 billion, compared to the consensus revenue estimate of $33.4 billion.

Medtronic Trading Down 0.2 %

Shares of Medtronic stock opened at $77.95 on Monday. Medtronic has a 12-month low of $68.84 and a 12-month high of $91.00. The company has a current ratio of 2.03, a quick ratio of 1.55 and a debt-to-equity ratio of 0.47. The stock has a market cap of $99.95 billion, a PE ratio of 28.35, a price-to-earnings-growth ratio of 2.27 and a beta of 0.82. The company has a 50-day moving average of $81.20 and a two-hundred day moving average of $83.19.

Medtronic (NYSE:MDT) last issued its quarterly earnings data on Thursday, May 23rd. The medical technology company reported $1.46 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.45 by $0.01. Medtronic had a return on equity of 13.47% and a net margin of 11.36%. The firm had revenue of $8.59 billion during the quarter, compared to the consensus estimate of $8.44 billion. During the same period in the previous year, the firm posted $1.57 EPS. The company’s quarterly revenue was up .5% compared to the same quarter last year. On average, research analysts anticipate that Medtronic will post 5.44 EPS for the current fiscal year.

Medtronic Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Friday, July 12th. Investors of record on Friday, June 28th were given a dividend of $0.70 per share. This is an increase from Medtronic’s previous quarterly dividend of $0.69. This represents a $2.80 annualized dividend and a dividend yield of 3.59%. The ex-dividend date was Friday, June 28th. Medtronic’s payout ratio is currently 101.82%.

Wall Street Analysts Forecast Growth

Several brokerages have weighed in on MDT. Wells Fargo & Company boosted their price target on Medtronic from $102.00 to $105.00 and gave the company an overweight rating in a report on Friday, May 24th. The Goldman Sachs Group began coverage on shares of Medtronic in a research note on Thursday, May 30th. They set a sell rating and a $83.00 price objective for the company. Needham & Company LLC reissued a hold rating on shares of Medtronic in a research note on Friday, May 24th. Truist Financial lowered their price objective on shares of Medtronic from $90.00 to $88.00 and set a hold rating for the company in a research note on Friday, May 24th. Finally, Royal Bank of Canada reissued a sector perform rating and set a $92.00 price objective on shares of Medtronic in a research note on Wednesday, June 5th. Two analysts have rated the stock with a sell rating, six have issued a hold rating and five have assigned a buy rating to the stock. According to data from MarketBeat, Medtronic presently has a consensus rating of Hold and an average price target of $91.09.

Insider Buying and Selling at Medtronic

In other Medtronic news, CEO Geoffrey Martha sold 19,113 shares of the company’s stock in a transaction dated Friday, June 7th. The shares were sold at an average price of $83.77, for a total value of $1,601,096.01. Following the completion of the transaction, the chief executive officer now directly owns 143,348 shares of the company’s stock, valued at approximately $12,008,261.96. The transaction was disclosed in a filing with the SEC, which is accessible through this link. 0.30% of the stock is currently owned by corporate insiders.

Medtronic Company Profile

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software.